The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 25, 2016

Filed:

Aug. 14, 2013
Applicant:

Central Iowa Health System, Des Moines, IA (US);

Inventors:

Charles J. Link, Jr., Clive, IA (US);

Tatiana Seregina, West Des Moines, IA (US);

Gabriela Rossi, Ankeny, IA (US);

Assignee:

CENTRAL IOWA HEALTH SYSTEM, Des Moines, IA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 35/00 (2006.01); A61K 39/385 (2006.01); C12N 5/09 (2010.01); C12N 5/22 (2006.01); A61K 39/395 (2006.01); A01K 67/027 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/395 (2013.01); A01K 67/0271 (2013.01); A01K 67/0275 (2013.01); A61K 39/0011 (2013.01); A01K 2217/05 (2013.01); A01K 2267/0331 (2013.01); A61K 2039/5152 (2013.01); A61K 2039/5156 (2013.01);
Abstract

The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.


Find Patent Forward Citations

Loading…